Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Heart Failure
Interventions: Calorie protein supplement, Control; Dietary Supplement · Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Coronary Heart Disease
Interventions: MPSK3169A, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 34
States / cities: Goodyear, Arizona • Carmichael, California • Spring Valley, California + 29 more

Conditions: Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura, Mesotheliomas Pleural, Mesothelioma Peritoneum, Cholangiocarcinoma, Cholangiocarcinoma Recurrent, Ovarian Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, High Grade Ovarian Serous Adenocarcinoma
Interventions: gavo-cel, fludarabine, cyclophosphamide, Nivolumab, Ipilimumab; Biological · Drug
Lead sponsor: TCR2 Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 10
States / cities: San Francisco, California • Miami, Florida • Chicago, Illinois + 6 more

Conditions: Pregnancy Related, Sexual Behavior, STD
Interventions: FLASH curriculum, Sexual Health Education for Adolescents; Behavioral
Lead sponsor: ETR Associates; Other
Eligibility: 14 Years to 18 Years
Enrollment: 1,597 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Scotts Valley, California

Conditions: Chronic Kidney Disease and Hypertension
Interventions: Baxdrostat/dapagliflozin, Baxdrostat/Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 17
States / cities: Surprise, Arizona • Hollywood, Florida • Port Charlotte, Florida + 14 more

Conditions: Myelodysplastic Syndrome
Interventions: 5-azacytidine; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Lung Cancer
Interventions: Cs-131 brachytherapy seeds; Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Childhood High-grade Cerebral Astrocytoma, Childhood Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions: tipifarnib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Colorectal Cancer
Interventions: Bevacizumab, Floxuridine, Irinotecan, Leucovorin; Biological · Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Metastatic Melanoma, Renal Cell Cancer
Interventions: aldesleukin; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Kidney Cancer, Melanoma (Skin)
Interventions: High-dose interleukin-2, genistein; Biological · Dietary Supplement
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: COVID-19
Interventions: PF-07321332 (nirmatrelvir)/ritonavir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 52
States / cities: Huntsville, Alabama • Granada Hills, California • Inglewood, California + 26 more

Conditions: Urothelial Carcinoma
Interventions: Not listed
Lead sponsor: Tampere University Hospital; Other
Eligibility: 18 Years to 100 Years
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Melanoma
Interventions: Pembrolizumab, Interleukin-2; Drug
Lead sponsor: Ralph Hauke; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Bipolar Disorder, Bipolar I Disorder, Bipolar II Disorder, Other Specified Bipolar and Related Disorder, Mood Instability, Child Mental Disorder, Adolescent - Emotional Problem
Interventions: Medication or psychosocial treatment; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 9 Years to 19 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • Pittsburgh, Pennsylvania + 1 more

Conditions: Colon Cancer, dMMR Colorectal Cancer
Interventions: Dostarlimab; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 2
States / cities: Iowa City, Iowa • Madison, Wisconsin

Conditions: Childhood Obesity
Interventions: Healthy Youth Living Program; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 12 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes, High Risk, Impaired Glucose Tolerance
Interventions: Teplizumab, Placebo infusion; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 8 Years to 45 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 17
States / cities: San Francisco, California • Stanford, California • Denver, Colorado + 13 more

Conditions: Lymphoma
Interventions: carboplatin, cyclophosphamide, etoposide, peripheral blood stem cell transplantation, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Northwestern University; Other
Eligibility: Up to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy
Interventions: Drospirenone/Ethinylestradiol, Midazolam, JNJ-64530440; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma
Interventions: Ad-RTS-hIL-12, Oral Veledimex - Arm 1 (Pediatric Brain Tumor), Oral Veledimex - Arm 2 (DIPG); Biological · Drug
Lead sponsor: Alaunos Therapeutics; Industry
Eligibility: 0 Years to 21 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Boston, Massachusetts

Conditions: Polypharmacy
Interventions: Clinical decision support (CDS)-Commitment nudge, Clinician education, Clinical decision support (CDS)-Justification nudge; Behavioral · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 786 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois • Pittsburgh, Pennsylvania

Conditions: High-grade Partial or Full Thickness Rotator Cuff Tears
Interventions: SOC (Standard of care), Cold and Compression; Other · Device
Lead sponsor: Ochsner Health System; Other
Eligibility: 35 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Kenner, Louisiana

Conditions: Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
Interventions: Epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Venetoclax, Lenalidomide, Pirtobrutinib; Biological · Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 23
States / cities: Birmingham, Alabama • California City, California • Duarte, California + 18 more

Search by objective public record fields.

High Calorie High Protein Nutrition Supplementation in Advanced Heart Failure

A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Rigorous Evaluation of High School FLASH

A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.

5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome

Cesium-131 Seed Brachytherapy Plus Subtotal Resection for Lung Cancer Patients

Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma

Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer

Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer

A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer

Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma

Children's Bipolar Network Treatment Trial I

Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers

Development of a Youth Healthy Living Program With Underserved Adolescents at Rochester Alternative Learning Center

Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin's Disease

Study in Women on the Effect of JNJ-64530440 on Oral Contraceptive and Midazolam, and the Effect of a High-fat Meal on JNJ-64530440

A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG

Reducing High-Risk Geriatric Polypharmacy Via EHR Nudges R01 Trial

Cold and Compression After Rotator Cuff Repair (RCR)

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome